' 
SCIENTIFIC SCORE
Possibly Effective
Based on 19 Researches
7.4
USERS' SCORE
Good
Based on 23 Reviews
8.9
Supplement Facts
Serving Size: 1 Veggie Capsule
Amount Per Serving
%DV
Alpha-Lipoic acid
300 mg
†
Benfotiamine
150 mg
†
Top Medical Research Studies
8
Benfotiamine shows promise for neuropathy
Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study).
Moderate relevance to treatment efficacy
We conducted a three-week randomized, placebo-controlled pilot study to see how benfotiamine could help patients with diabetic polyneuropathy.
Forty inpatients received either benfotiamine or a placebo, and we found that those taking benfotiamine experienced a significant improvement in neuropathy symptoms, particularly pain reduction.
Although some measures showed no major differences, more individuals in the benfotiamine group felt better overall.
Forty inpatients received either benfotiamine or a placebo, and we found that those taking benfotiamine experienced a significant improvement in neuropathy symptoms, particularly pain reduction.
Although some measures showed no major differences, more individuals in the benfotiamine group felt better overall.
Read More
7
Benfotiamine shows potential benefits
Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study.
Moderately relevant to treatment options.
We conducted a double-blind, placebo-controlled study to assess the effectiveness of benfotiamine in treating diabetic polyneuropathy.
Out of 181 screened patients, 165 with the condition were divided into three groups receiving either 600 mg, 300 mg of benfotiamine, or a placebo. After six weeks, we observed some improvements in neuropathy symptoms, particularly with the higher dosage, although results didn’t meet significant thresholds for all measures.
While benfotiamine shows potential benefits, further research is needed to confirm these findings and explore its role in treating this condition.
Out of 181 screened patients, 165 with the condition were divided into three groups receiving either 600 mg, 300 mg of benfotiamine, or a placebo. After six weeks, we observed some improvements in neuropathy symptoms, particularly with the higher dosage, although results didn’t meet significant thresholds for all measures.
While benfotiamine shows potential benefits, further research is needed to confirm these findings and explore its role in treating this condition.
Read More
8
Alpha-lipoic acid reduces AGEs
Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy.
Direct effect on T2DM neuropathy
We investigated the potential benefits of alpha-lipoic acid (ALA) for patients with type 2 diabetes mellitus (T2DM) suffering from neuropathy. Over six months, we treated 54 patients with a daily dose of 600 mg of ALA while keeping their current oral medications unchanged. We also included a control group of 24 matched individuals who did not experience neuropathy.
Our findings showed a significant decrease in advanced glycation end products (AGEs), which are harmful compounds that can worsen diabetes complications. The levels of AGEs dropped from 11.89 to 10.95 AU/μg, reflecting the positive impact ALA treatment can have. Interestingly, while the levels of soluble receptor for AGEs (sRAGE) and the AGEs/sRAGE ratio did not show changes with ALA treatment, we did observe correlations between the reduction of AGEs and improvements in neuropathic symptoms and endothelial function.
Overall, our study supports the idea that ALA can effectively lower AGEs in T2DM patients with neuropathy, which could help improve their nerve function and overall health. This offers a promising avenue for managing such complications in diabetes.
Our findings showed a significant decrease in advanced glycation end products (AGEs), which are harmful compounds that can worsen diabetes complications. The levels of AGEs dropped from 11.89 to 10.95 AU/μg, reflecting the positive impact ALA treatment can have. Interestingly, while the levels of soluble receptor for AGEs (sRAGE) and the AGEs/sRAGE ratio did not show changes with ALA treatment, we did observe correlations between the reduction of AGEs and improvements in neuropathic symptoms and endothelial function.
Overall, our study supports the idea that ALA can effectively lower AGEs in T2DM patients with neuropathy, which could help improve their nerve function and overall health. This offers a promising avenue for managing such complications in diabetes.
Read More
Most Useful Reviews
9.5
Relief from symptoms
This is the best mixture for neuropathy (both diabetic and otherwise). I eventually increased to two a day, which made my urine smell, but it relieved 90% of my neuropathy symptoms in my feet. Be consistent and use sensible care practices to regain your feet. It’s the best and least expensive gift I’ve ever given myself.
Read More
9.5
Quality of life
I experienced eight continuous hours of sleep, which felt miraculous. Initially, I doubted it could help, having tried many remedies before. The only previous relief came from Tramadol, which I wanted to avoid. After reading about ALA, I ordered this product and took it two nights later. This was the first time in almost six months that I slept through the night, and my legs felt significantly better. I've been using it since early November 2015, and it has remarkably improved my quality of life.
Read More
9.5
Effective for pain
Excellent product. This aids significantly with the pain of peripheral neuropathy, often working as effectively, if not better, than prescription gabapentin.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 19 Researches
7.4
- All Researches
8
Alpha-lipoic acid reduces AGEs
Alpha-Lipoic Acid Treatment Reduces the Levels of Advanced End Glycation Products in Type 2 Diabetes Patients with Neuropathy.
Direct effect on T2DM neuropathy
We investigated the potential benefits of alpha-lipoic acid (ALA) for patients with type 2 diabetes mellitus (T2DM) suffering from neuropathy. Over six months, we treated 54 patients with a daily dose of 600 mg of ALA while keeping their current oral medications unchanged. We also included a control group of 24 matched individuals who did not experience neuropathy.
Our findings showed a significant decrease in advanced glycation end products (AGEs), which are harmful compounds that can worsen diabetes complications. The levels of AGEs dropped from 11.89 to 10.95 AU/μg, reflecting the positive impact ALA treatment can have. Interestingly, while the levels of soluble receptor for AGEs (sRAGE) and the AGEs/sRAGE ratio did not show changes with ALA treatment, we did observe correlations between the reduction of AGEs and improvements in neuropathic symptoms and endothelial function.
Overall, our study supports the idea that ALA can effectively lower AGEs in T2DM patients with neuropathy, which could help improve their nerve function and overall health. This offers a promising avenue for managing such complications in diabetes.
Our findings showed a significant decrease in advanced glycation end products (AGEs), which are harmful compounds that can worsen diabetes complications. The levels of AGEs dropped from 11.89 to 10.95 AU/μg, reflecting the positive impact ALA treatment can have. Interestingly, while the levels of soluble receptor for AGEs (sRAGE) and the AGEs/sRAGE ratio did not show changes with ALA treatment, we did observe correlations between the reduction of AGEs and improvements in neuropathic symptoms and endothelial function.
Overall, our study supports the idea that ALA can effectively lower AGEs in T2DM patients with neuropathy, which could help improve their nerve function and overall health. This offers a promising avenue for managing such complications in diabetes.
Read More
8
Alpha-lipoic acid and neuropathy insights
Expanded Clinical Phenotype and the Role of Untargeted Metabolomics Analysis in Confirming the Diagnosis of Sodium-Dependent Multivitamin Transporter Deficiency.
Moderate relevance to neuropathy treatment
We explored the effects of alpha-lipoic acid in the context of sodium-dependent multivitamin transporter deficiency (SMVTD), a rare condition resulting from loss-of-function variants in the SLC5A6 gene. In a detailed case of a 25-year-old woman, whose symptoms included developmental delays, epilepsy, and neurocognitive challenges, we observed an intriguing combination of treatments.
Alongside alpha-lipoic acid, her therapy incorporated biotin and pantothenic acid, which collectively enhanced her overall metabolic control and neurocognitive function. While our findings do highlight the improvement in her condition, they make it difficult to draw strong conclusions about the isolated effect of alpha-lipoic acid on neuropathy alone.
Ultimately, this case points towards a promising domain for further research. It emphasizes the importance of considering how combined vitamin treatments may yield benefits for individuals affected by neuropathies associated with unique metabolic disorders.
Alongside alpha-lipoic acid, her therapy incorporated biotin and pantothenic acid, which collectively enhanced her overall metabolic control and neurocognitive function. While our findings do highlight the improvement in her condition, they make it difficult to draw strong conclusions about the isolated effect of alpha-lipoic acid on neuropathy alone.
Ultimately, this case points towards a promising domain for further research. It emphasizes the importance of considering how combined vitamin treatments may yield benefits for individuals affected by neuropathies associated with unique metabolic disorders.
Read More
8
Benfotiamine effective for neuropathy
[Pathomechanism of diabetic neuropathy: background of the pathogenesis-oriented therapy].
High relevance to neuropathy treatment
We examined the complexities of diabetic neuropathy and the role of benfotiamine in its management. Recent findings confirm that benfotiamine can inhibit harmful pathways triggered by high blood sugar, thus helping to promote healthier nerve function. Numerous clinical trials worldwide have shown it to be effective.
Furthermore, benfotiamine works alongside other treatments like alpha-lipoic acid to improve symptoms gradually. By focusing on these new therapeutic approaches, we can better address neuropathy and enhance quality of life for those affected.
Furthermore, benfotiamine works alongside other treatments like alpha-lipoic acid to improve symptoms gradually. By focusing on these new therapeutic approaches, we can better address neuropathy and enhance quality of life for those affected.
Read More
8
Benfotiamine's potential in neuropathy
The multifaceted therapeutic potential of benfotiamine.
Moderate relevance in neuropathy study
We examined the effects of benfotiamine, a synthetic derivative of vitamin B1, on neuropathy. This compound increases intracellular thiamine diphosphate, which helps combat advanced glycation end products (AGEs) that contribute to nerve damage, particularly in diabetes.
While benfotiamine shows promise due to its anti-AGE properties and potential benefits for diabetic complications like neuropathy, recent studies offer mixed results regarding its overall effectiveness.
Thus, while it may be helpful in some contexts, the results highlight the need for further investigation to confirm its benefits for neuropathy.
While benfotiamine shows promise due to its anti-AGE properties and potential benefits for diabetic complications like neuropathy, recent studies offer mixed results regarding its overall effectiveness.
Thus, while it may be helpful in some contexts, the results highlight the need for further investigation to confirm its benefits for neuropathy.
Read More
8
Benfotiamine reduces pain in rats
Benfotiamine relieves inflammatory and neuropathic pain in rats.
Animal model shows effective results
We explored the potential of benfotiamine in alleviating inflammatory and neuropathic pain through a detailed study with rats. By inducing pain through specific methods, we noted significant reductions in pain-related behaviors when benfotiamine was administered at varying doses.
The findings suggest that benfotiamine shows promise in reducing pain from different causes, hinting at its potential benefits for humans suffering from nerve pain. While this research is promising, further studies are needed to fully understand its effects in human trials.
The findings suggest that benfotiamine shows promise in reducing pain from different causes, hinting at its potential benefits for humans suffering from nerve pain. While this research is promising, further studies are needed to fully understand its effects in human trials.
Read More
User Reviews
USERS' SCORE
Good
Based on 23 Reviews
8.9
- All Reviews
- Positive Reviews
- Negative Reviews
9.5
Relief from symptoms
This is the best mixture for neuropathy (both diabetic and otherwise). I eventually increased to two a day, which made my urine smell, but it relieved 90% of my neuropathy symptoms in my feet. Be consistent and use sensible care practices to regain your feet. It’s the best and least expensive gift I’ve ever given myself.
Read More
9.5
Quality of life
I experienced eight continuous hours of sleep, which felt miraculous. Initially, I doubted it could help, having tried many remedies before. The only previous relief came from Tramadol, which I wanted to avoid. After reading about ALA, I ordered this product and took it two nights later. This was the first time in almost six months that I slept through the night, and my legs felt significantly better. I've been using it since early November 2015, and it has remarkably improved my quality of life.
Read More
9.5
Effective for pain
Excellent product. This aids significantly with the pain of peripheral neuropathy, often working as effectively, if not better, than prescription gabapentin.
9.5
Keeps pain checked
I began using this due to a recent onset of neuropathy pain in my feet from diabetes. Thus far, taking two pills a day has been working excellently for me.
8.8
Quick recovery
After breaking my ankle at 62, I began feeling tingling in my foot about 1.5 years later, assuming it was scar tissue affecting a nerve. Within two weeks of using this product, my symptoms improved remarkably. It's commonly used for diabetic peripheral neuropathy, but I find it also helps with my sciatic flare-ups. A great product!
Read More
